The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1136-1141

  Schmandt, Rosemarie E ^a   Bennett, Marsha ^a   Clifford, Stephanie ^a   Thornton, Angela ^a   Jiang, Feng ^a   Broaddus, Russell R ^a   Sun, Charlotte C ^a   Lu, Karen H ^a   Sood, Anil K ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BRK; Fluorescence in situ hybridization; Immunohistochemistry; Ovarian cancer; PTK6; Tyrosine kinase; Western blot analysis

Indexed keywords

PROTEIN BRK; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 33751119545     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.2953     Document Type: Article

References (47)

1. American Cancer Society, Cancer Facts & Figures 2005. Atlanta: American Cancer Society; 2005.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5:19-24.
3. Seiden MV. Ovarian cancer. Oncologist 2001; 6:327-32.
4. Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother 2001; 2:109-24.
5. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19:5548-5557.
6. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-34.
7. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
9. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347:1593-603.
10. McCormick F. Small-molecule inhibitors of cell signalling. Curr Opin Biotech 2000; 11:593-597.
11. Arteaga CL. Inhibiting tyrosine kinases: Successes and limitations. Cancer Biol Ther 2003; 2:S79-83.
12. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2:296-313.
13. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Protein kinases as targets for anticancer agents: From inhibitors to useful drugs. Pharmacol Ther 2002; 93:79-98.
14. Arteaga C. Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol 2003; 30:3-14.
15. Fry DW. Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res 2003; 284:131-9.
16. Roskoski Jr R. STI-571: An anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 2003; 309:709-17.
17. Serfas MS, Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src like tyrosine kinases. Oncol Res 2003; 13:409-19.
18. Harvey AJ, Crompton MR. The Brk protein tyrosine kinase as a therapeutic target in cancer: Opportunities and challenges. Anticancer Drugs 2004; 15:107-11.
19. Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ, Gusterson BA, Crompton MR.. Cloning and characterisation of cDNAs encoding a novel nonreceptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 1994; 9:2383-90.
20. Lee ST, Strunk KM, Spritz RA. A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene 1993; 8:3403-10.
21. Siyanova EY, Serfas MS, Mazo IA, Tyner AL. Tyrosine kinase gene expression in the mouse small intestine. Oncogene 1994; 9:2053-7.
22. Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B, Thomason A, Tyner AL. A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene. 1995; 10:349-57.
23. Vasioukhin V, Tyner AL. A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. Proc Natl Acad Sci USA 1997; 94:14477-82.
24. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003; 22:4212-20.
25. Kamalati T, Jolin HE, Mitchell PJ, et al. Brk, a breast tumor-derived nonreceptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996; 271:30956-63.
26. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997; 15:799-805.
27. Vasioukhin V, Tyner AL. A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. Proc Natl Acad Sci USA 1997; 94:14477-82.
28. Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, Abbott CM, Tyner AL. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res. 1999; 5:1767-77.
29. Mitchell PJ, Barker KT, Shipley J, Crompton MR. Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene 1997; 15:1497-502.
30. Park SH, Lee KH, Kim H, Lee ST. Assignment of the human PTK6 gene encoding a nonreceptor protein tyrosine kinase to 20q13.3 by fluorescence in situ hybridization. Cytogenet Cell Genet 1997; 77:271-2.
31. Suzuki S, Moore DH 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res. 2000; 60:5382-5.
32. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, Berchuck A, Pinkel D, Albertson D, Mills GB. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol. 2003; 88:S16-21.
33. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001; 91:534-40.
34. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 2000; 6:1833-9.
35. Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, Yakushiji M, Testa JR. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer. 1997; 20:320-8.
36. Watanabe T, Imoto I, Katahira T, Hirasawa A, Ishiwata I, Emi M, Takayama M, Sato A, Inazawa J. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers. Jpn J Cancer Res. 2002; 93:1114-22.
37. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Mod Path. 2002; 15:202A-3A.
38. Wilks AF. Cloning members of protein-tyrosine kinase family using polymerase chain reaction. Methods in Enzymology 1991; 200:533-545.
39. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J 1995; 9:576-96.
40. Qiu H, Miller WT. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem 2002; 277:34634-41.
41. Mitchell PJ, Sara EA, Crompton MR. A novel adaptor-like protein which is a substrate for the nonreceptor tyrosine kinase, BRK. Oncogene 2000; 19:4273-82.
42. Derry JJ, Richard S, Valderrama Carvajal H, Ye X, Vasioukhin V, Cochrane AW, Chen T, Tyner AL. Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol. 2000; 20:6114-26.
43. Coyle JH, Guzik BW, Bor YC, Jin L, Eisner-Smerage L, Taylor SJ, Rekosh D, Hammarskjold ML. Sam68 enhances the cytoplasmic utilization of intron-containing RNA and is functionally regulated by the nuclear kinase Sik/BRK. Mol Cell Biol. 2003; 23:92-103.
44. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 2004; 24:10558-72.
45. Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, Lange CA. Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem 2005; 280:1982-91.
46. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev 2001; 22:255-88.
47. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003; 22:5006-10.